Brasil, S, Allocca, M, Magrinho, SCM, Santos, I, Raposo, M, Francisco, R et al.. Systematic Review: Drug Repositioning for Congenital Disorders of Glycosylation (CDG). Int J Mol Sci. 2022;23 (15):. doi: 10.3390/ijms23158725. PubMed PMID:35955863 .
Pearson, C, Schapiro, L, Pearson, SD. The next generation of rare disease drug policy: ensuring both innovation and affordability. J Comp Eff Res. 2022; :. doi: 10.2217/cer-2022-0120. PubMed PMID:35946484 .
Blonda, A, Denier, Y, Huys, I, Kawalec, P, Simoens, S. How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries. Front Pharmacol. 2022;13 :902150. doi: 10.3389/fphar.2022.902150. PubMed PMID:35928274 PubMed Central PMC9343828.
Mazzucato, M, Minichiello, C, Visonà Dalla Pozza, L, Vianello, A, Toto, E, De Lorenzi, M et al.. [The impact of the use of treatments not included in the reimbursement classes in the care of rare patients: a real world study.]. Recenti Prog Med. ;113 (7):440-450. doi: 10.1701/3850.38339. PubMed PMID:35852080 .
Crisafulli, S, Trifirò, G. [The role of real-world evidence for the study of rare diseases epidemiology and the post-marketing evaluation of orphan drugs.]. Recenti Prog Med. ;113 (7):425-429. doi: 10.1701/3850.38336. PubMed PMID:35852077 .
Costa, E, Grimaldi, G, Del Grosso, V, Isgrò, A, Genazzani, A. [Access to medicines for rare diseases: regulatory aspects and public health priorities.]. Recenti Prog Med. ;113 (7):415-424. doi: 10.1701/3850.38335. PubMed PMID:35852076 .
Costa, E, Magrini, N. [Harmonizing development, approval and access of drugs for rare diseases in Europe.]. Recenti Prog Med. ;113 (7):407-410. doi: 10.1701/3850.38333. PubMed PMID:35852074 .
Wu, X, Xu, W, Yu, M, Zhang, F, Wang, H. Clinical trials of orphan drugs in China over the decade 2012-2022: Opportunities and challenges. Pharmacol Res. 2022;182 :106349. doi: 10.1016/j.phrs.2022.106349. PubMed PMID:35835367 .
Stafinski, T, Glennie, J, Young, A, Menon, D. HTA decision-making for drugs for rare diseases: comparison of processes across countries. Orphanet J Rare Dis. 2022;17 (1):258. doi: 10.1186/s13023-022-02397-4. PubMed PMID:35804398 PubMed Central PMC9264608.
Zhou, N, Ji, H, Li, Z, Hu, J, Xie, JH, Feng, YH et al.. Influencing Factors of Health Technology Assessment to Orphan Drugs: Empirical Evidence in England, Scotland, Canada, and Australia. Front Public Health. 2022;10 :861067. doi: 10.3389/fpubh.2022.861067. PubMed PMID:35784205 PubMed Central PMC9247336.
Gabison, EE, Guindolet, D. Neurotrophic Keratitis: A rare disease that requires proactive screening and orphan drug treatments. Ocul Surf. 2022;25 :154. doi: 10.1016/j.jtos.2022.06.008. PubMed PMID:35781074 .
Mohammadshahi, M, Olyaeemanesh, A, Ehsani-Chimeh, E, Mobinizadeh, M, Fakoorfard, Z, Akbari Sari, A et al.. Methods and criteria for the assessment of orphan drugs: a scoping review. Int J Technol Assess Health Care. 2022;38 (1):e59. doi: 10.1017/S0266462322000393. PubMed PMID:35730573 .
Fontrier, AM. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations. Soc Sci Med. 2022;306 :115119. doi: 10.1016/j.socscimed.2022.115119. PubMed PMID:35700552 .
Gandini, E, Marcou, G, Bonachera, F, Varnek, A, Pieraccini, S, Sironi, M et al.. Molecular Similarity Perception Based on Machine-Learning Models. Int J Mol Sci. 2022;23 (11):. doi: 10.3390/ijms23116114. PubMed PMID:35682792 PubMed Central PMC9181189.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.